Home › Urothelial (Transitional Cell) Carcinoma › Illinois › Chicago
Pag-aaral pangklinika para sa Urothelial (Transitional Cell) Carcinoma sa Chicago, IL
14 pag-aaral para sa Urothelial (Transitional Cell) Carcinoma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Chicago (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Nagre-recruitPhase 3
- University of Illinois, Chicago
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #26, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Nagre-recruitObservasyonal na pag-aaral
- Northwestern University, Chicago
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Nagre-recruitPhase 1/2
- University of Chicago Medical Center ( Site 1037), Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Nagre-recruitPhase 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Nagre-recruitPhase 2
- UChicago Medicine - River East, Chicago
- University of Chicago Medical Center, Chicago
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Nagre-recruitPhase 1/2
- The University of Chicago Medical Center - Oncology, Chicago
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Nagre-recruitPhase 2
- Site 02-012 - University of Chicago, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Chicago
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
Nagre-recruitObservasyonal na pag-aaral
- Jesse Brown Department Of Veterans Affairs Medical Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Nagre-recruitPhase 1
- University of Chicago, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Nagre-recruitPhase 2
- Northwestern University, Chicago
Pag-aaral para sa Urothelial (Transitional Cell) Carcinoma sa ibang lungsod
- Nashville, TN23 pag-aaral
- New York City, NY22 pag-aaral
- Houston, TX19 pag-aaral
- Dallas, TX18 pag-aaral
- Edison, NJ18 pag-aaral
- Los Angeles, CA17 pag-aaral
- Queens, NY15 pag-aaral
- Arlington, VA12 pag-aaral
- Boston, MA11 pag-aaral
- San Antonio, TX11 pag-aaral
- Austin, TX10 pag-aaral
- Orange, CA10 pag-aaral
Iba pang pag-aaral sa Chicago
- Non-Small Cell Lung Cancer61 pag-aaral
- Kanser sa Suso59 pag-aaral
- Kanser (lahat ng uri)51 pag-aaral
- Metastatic Cancer45 pag-aaral
- Kanser sa Prostate45 pag-aaral
- Kanser sa Baga41 pag-aaral
- Obesity41 pag-aaral
- Kanser sa Ovary36 pag-aaral
- Colorectal Cancer34 pag-aaral
- Stroke34 pag-aaral
- Pagkabigo ng Puso31 pag-aaral
- Overweight29 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.